| 主权项 |
1. A method of treating a cardiovascular disease or disorder associated with phospholamban phoshorylation, comprising administering to a patient in need thereof a therapeutically effective amount of at least one compound of formula (I) or a physiologically acceptable salt thereof: wherein L1, L2 and L3 independently denote C1-C4-alkylene optionally substituted with one phenyl; Ar1, Ar2 and Ar3 independently denote phenyl optionally substituted with one or more R; wherein R independently denotes F, Cl, Br, I, C1-C4-haloalkyl, OR1, SR1, NO2, NR2R3, R4, C(═O)Y, SO3H, C1-C4-alkyl, C1-C4-alkyl-phenyl, a 5-membered heteroaryl; or a phenyl substituted with a 5-membered heteroaryl; R1 denotes H, C1-C4-alkyl or C1-C4-alkyl-phenyl; or together two adjacent OR1 groups denote —O—CH2—O—; R2 and R3 independently denote H or C1-C4-alkyl; or NR2R3 denotes —NHC(═O)—NHAr5; or together two adjacent NR2R3 groups denote —NR2—CH—N— or —NR2—CH2—NR2—; or together with an adjacent OR1 group, NR2R3 denotes —NR2—CH2—O— or —N—CH—O—; or together with an adjacent SR1 group, NR2R3 denotes —NR2—CH2—S— or —N—CH—S—; Ar5 denotes phenyl optionally substituted with Rh; Rh denotes halogen or C1-C4 alkyl; R4 denotes C1-C4-alkyl; or together with an adjacent OR1 group, R4 denotes —CH2CH2—O—; or together two adjacent R4 groups denote —(CH)4— or —(CH2)4—; Y denotes OR5 or NR6R7; R5 denotes H or C1-C4-alkyl; and R6 and R7 independently denote H, C1-C8-alkyl or C3-C6 cycloalkyl; wherein the cardiovascular disease or disorder associated with phospholamban phosphorylation is selected from congenital heart failure, myocardial infarction, post infarction heart failure, congestive heart failure, reperfusion damage, dilated cardiomyopathy, and arrhythmia. |
